Journal Article
. 2008 Feb; 105(8):3005-10.
doi: 10.1073/pnas.0712237105.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

F Stephen Hodi 1 Marcus Butler  Darryl A Oble  Michael V Seiden  Frank G Haluska  Andrea Kruse  Suzanne Macrae  Marybeth Nelson  Christine Canning  Israel Lowy  Alan Korman  David Lautz  Sara Russell  Michael T Jaklitsch  Nikhil Ramaiya  Teresa C Chen  Donna Neuberg  James P Allison  Martin C Mihm  Glenn Dranoff  
  • PMID: 18287062
  •     37 References
  •     281 citations


Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor destruction in some subjects. Nonetheless, patients that respond also frequently manifest serious inflammatory pathologies, raising the possibility that the therapeutic and toxic effects of CTLA-4 blockade might be linked. Here we show that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients. The application of this sequential immunotherapy to advanced ovarian carcinoma patients also revealed that tumor destruction and severe inflammatory pathology could be dissociated, although further refinements are required to increase clinical responses and to minimize toxicity in this population. The extent of therapy-induced tumor necrosis was linearly related to the natural logarithm of the ratio of intratumoral CD8(+) effector T cells to FoxP3(+) regulatory T cells (Tregs) in posttreatment biopsies. Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
Masahisa Jinushi, F Stephen Hodi, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2006 Jun 07; 103(24). PMID: 16754847    Free PMC article.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E Beck, Joseph A Blansfield, +12 authors, James C Yang.
J Clin Oncol, 2006 May 20; 24(15). PMID: 16710025    Free PMC article.
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells.
A M Doyle, A C Mullen, +5 authors, S L Reiner.
J Exp Med, 2001 Oct 03; 194(7). PMID: 11581312    Free PMC article.
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
R P Sutmuller, L M van Duivenvoorde, +6 authors, C J Melief.
J Exp Med, 2001 Sep 19; 194(6). PMID: 11560997    Free PMC article.
Highly Cited.
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
S Read, V Malmström, F Powrie.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899916    Free PMC article.
Highly Cited.
DC-based cancer vaccines.
Eli Gilboa.
J Clin Invest, 2007 May 04; 117(5). PMID: 17476349    Free PMC article.
Highly Cited. Review.
Cytokines in cancer pathogenesis and cancer therapy.
Glenn Dranoff.
Nat Rev Cancer, 2004 Jan 07; 4(1). PMID: 14708024
Highly Cited. Review.
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.
Simon Read, Rebecca Greenwald, +5 authors, Fiona Powrie.
J Immunol, 2006 Sep 20; 177(7). PMID: 16982872    Free PMC article.
Highly Cited.
The emerging role of CTLA-4 as an immune attenuator.
C B Thompson, J P Allison.
Immunity, 1997 Nov 14; 7(4). PMID: 9354465
Highly Cited. Review.
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
Mark J Smyth, Gavin P Dunn, Robert D Schreiber.
Adv Immunol, 2006 May 30; 90. PMID: 16730260
Highly Cited. Review.
Measuring response in a post-RECIST world: from black and white to shades of grey.
Laura C Michaelis, Mark J Ratain.
Nat Rev Cancer, 2006 Apr 25; 6(5). PMID: 16633367
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A A Hurwitz, B A Foster, +5 authors, J P Allison.
Cancer Res, 2000 May 16; 60(9). PMID: 10811122
Highly Cited.
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.
Masahisa Jinushi, Yukoh Nakazaki, +3 authors, Glenn Dranoff.
J Clin Invest, 2007 Jun 09; 117(7). PMID: 17557120    Free PMC article.
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
Ajay V Maker, James C Yang, +11 authors, Steven A Rosenberg.
J Immunother, 2006 Jun 27; 29(4). PMID: 16799341    Free PMC article.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
Hironori Ueda, Joanna M M Howson, +50 authors, Stephen C L Gough.
Nature, 2003 May 02; 423(6939). PMID: 12724780
Highly Cited.
The consensus coding sequences of human breast and colorectal cancers.
Tobias Sjöblom, Siân Jones, +26 authors, Victor E Velculescu.
Science, 2006 Sep 09; 314(5797). PMID: 16959974
Highly Cited.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin Sanderson, Ronald Scotland, +9 authors, Jeffrey Weber.
J Clin Oncol, 2004 Dec 23; 23(4). PMID: 15613700
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, +6 authors, T W Mak.
Science, 1995 Nov 10; 270(5238). PMID: 7481803
Highly Cited.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Peter Attia, Giao Q Phan, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087944    Free PMC article.
Highly Cited.
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A A Hurwitz, T F Yu, D R Leach, J P Allison.
Proc Natl Acad Sci U S A, 1998 Aug 26; 95(17). PMID: 9707601    Free PMC article.
Highly Cited.
Human T cell responses against melanoma.
Thierry Boon, Pierre G Coulie, Benoît J Van den Eynde, Pierre van der Bruggen.
Annu Rev Immunol, 2006 Mar 23; 24. PMID: 16551247
Highly Cited. Review.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, +15 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2005 Dec 14; 102(51). PMID: 16344461    Free PMC article.
Highly Cited.
High-throughput oncogene mutation profiling in human cancer.
Roman K Thomas, Alissa C Baker, +51 authors, Levi A Garraway.
Nat Genet, 2007 Feb 13; 39(3). PMID: 17293865
Highly Cited.
The immune paradox of sarcoidosis and regulatory T cells.
Makoto Miyara, Zahir Amoura, +9 authors, Guy Gorochov.
J Exp Med, 2006 Jan 25; 203(2). PMID: 16432251    Free PMC article.
Highly Cited.
Immunosuppressive strategies that are mediated by tumor cells.
Gabriel A Rabinovich, Dmitry Gabrilovich, Eduardo M Sotomayor.
Annu Rev Immunol, 2006 Dec 01; 25. PMID: 17134371    Free PMC article.
Highly Cited. Review.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Self-recognition and tumor response to immunotherapy.
Marc S Ernstoff.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087939
CTLA-4 blockade: autoimmunity as treatment.
Dilnawaz Kapadia, Lawrence Fong.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204008
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
B Salomon, J A Bluestone.
Annu Rev Immunol, 2001 Mar 13; 19. PMID: 11244036
Highly Cited. Review.
Autoantibodies frequently detected in patients with aplastic anemia.
Naoto Hirano, Marcus O Butler, +7 authors, Lee M Nadler.
Blood, 2003 Aug 30; 102(13). PMID: 12947009
Checkpoint blockade in cancer immunotherapy.
Alan J Korman, Karl S Peggs, James P Allison.
Adv Immunol, 2006 May 30; 90. PMID: 16730267    Free PMC article.
Highly Cited. Review.
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
James M Reuben, Bang-Ning Lee, +7 authors, Luis H Camacho.
Cancer, 2006 Apr 15; 106(11). PMID: 16615096
[Immunmodulatory antibodies in the treatment of skin cancer].
D Schrama, A Hauschild, J C Becker.
Hautarzt, 2008 Sep 09; 59(10). PMID: 18777167
Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.
Richard G Carroll, Carmine Carpenito, +9 authors, Carl H June.
PLoS One, 2008 Sep 27; 3(9). PMID: 18818761    Free PMC article.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Asad Bashey, Bridget Medina, +11 authors, Edward D Ball.
Blood, 2008 Nov 01; 113(7). PMID: 18974373    Free PMC article.
Highly Cited.
Immunotherapy of autoimmunity and cancer: the penalty for success.
Rachel R Caspi.
Nat Rev Immunol, 2008 Nov 15; 8(12). PMID: 19008897    Free PMC article.
Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.
Seunghee Kim-Schulze, Hong Sung Kim, +2 authors, Howard L Kaufman.
Mol Ther, 2008 Nov 27; 17(2). PMID: 19034262    Free PMC article.
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Jianda Yuan, Sacha Gnjatic, +17 authors, Jedd D Wolchok.
Proc Natl Acad Sci U S A, 2008 Dec 17; 105(51). PMID: 19074257    Free PMC article.
Highly Cited.
Cytotoxic T-lymphocyte antigen 4 blockade augments the T-cell response primed by attenuated Listeria monocytogenes resulting in more rapid clearance of virulent bacterial challenge.
Jared H Rowe, Tanner M Johanns, +2 authors, Sing Sing Way.
Immunology, 2009 Feb 05; 128(1 Suppl). PMID: 19191906    Free PMC article.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Hong Chen, Chrysoula I Liakou, +8 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2009 Feb 10; 106(8). PMID: 19202079    Free PMC article.
Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.
Ignacio Melero, Ivan Martinez-Forero, +3 authors, Lieping Chen.
Clin Cancer Res, 2009 Feb 26; 15(5). PMID: 19240168    Free PMC article.
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
Wim Maes, Georgina Galicia Rosas, +4 authors, Stefaan W Van Gool.
Neuro Oncol, 2009 Apr 02; 11(5). PMID: 19336528    Free PMC article.
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Darryl A Oble, Robert Loewe, Ping Yu, Martin C Mihm.
Cancer Immun, 2009 Apr 03; 9. PMID: 19338264    Free PMC article.
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.
D Schönfeld, G Matschiner, +8 authors, A Skerra.
Proc Natl Acad Sci U S A, 2009 May 07; 106(20). PMID: 19416843    Free PMC article.
Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms.
Masahisa Jinushi, Marimo Sato, +5 authors, Hideaki Tahara.
J Exp Med, 2009 May 13; 206(6). PMID: 19433619    Free PMC article.
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
Vincent T Ho, Matthew Vanneman, +14 authors, Robert Soiffer.
Proc Natl Acad Sci U S A, 2009 Sep 01; 106(37). PMID: 19717467    Free PMC article.
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Stephen M Ansell, Sara A Hurvitz, +10 authors, John M Timmerman.
Clin Cancer Res, 2009 Oct 08; 15(20). PMID: 19808874    Free PMC article.
Highly Cited.
Clinical importance of B7-H3 expression in human pancreatic cancer.
I Yamato, M Sho, +7 authors, Y Nakajima.
Br J Cancer, 2009 Oct 22; 101(10). PMID: 19844235    Free PMC article.
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Amorette Barber, Agnieszka Rynda, Charles L Sentman.
J Immunol, 2009 Nov 17; 183(11). PMID: 19915047    Free PMC article.
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
William Humphries, Jun Wei, John H Sampson, Amy B Heimberger.
Neurosurg Clin N Am, 2009 Dec 01; 21(1). PMID: 19944972    Free PMC article.
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
Lana E Kandalaft, Nathan Singh, +4 authors, George Coukos.
Gynecol Oncol, 2009 Dec 05; 116(2). PMID: 19959212    Free PMC article.
Redirecting the immune response: role of adoptive T cell therapy.
Anna Mondino, Valérie Dardalhon, +2 authors, Naomi Taylor.
Hum Gene Ther, 2010 Mar 06; 21(5). PMID: 20201627    Free PMC article.
Whole tumor antigen vaccines.
Cheryl Lai-Lai Chiang, Fabian Benencia, George Coukos.
Semin Immunol, 2010 Apr 02; 22(3). PMID: 20356763    Free PMC article.
In situ regulation of DC subsets and T cells mediates tumor regression in mice.
Omar A Ali, Dwaine Emerich, Glenn Dranoff, David J Mooney.
Sci Transl Med, 2010 Apr 07; 1(8). PMID: 20368186    Free PMC article.
The biologic importance of tumor-infiltrating lymphocytes.
F Stephen Hodi, Glenn Dranoff.
J Cutan Pathol, 2010 May 28; 37 Suppl 1. PMID: 20482675    Free PMC article.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Maha Zohra Ladjemi, William Jacot, +2 authors, Isabelle Navarro-Teulon.
Cancer Immunol Immunother, 2010 Jun 10; 59(9). PMID: 20532501    Free PMC article.
Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ.
Kanako Shimizu, Michihiro Hidaka, +4 authors, Shin-ichiro Fujii.
Int J Hematol, 2010 Jun 17; 92(1). PMID: 20552304
FOXP3+ regulatory T cells in the human immune system.
Shimon Sakaguchi, Makoto Miyara, Cristina M Costantino, David A Hafler.
Nat Rev Immunol, 2010 Jun 19; 10(7). PMID: 20559327
Highly Cited. Review.
CTLA-4 blockade: therapeutic potential in cancer treatments.
Ahmad A Tarhini, Fatima Iqbal.
Onco Targets Ther, 2010 Jul 10; 3. PMID: 20616954    Free PMC article.
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.
Chrystelle Brignone, Maya Gutierrez, +9 authors, Frédéric Triebel.
J Transl Med, 2010 Jul 27; 8. PMID: 20653948    Free PMC article.
GM-CSF-secreting vaccines for solid tumors: moving forward.
Richa Gupta, Leisha A Emens.
Discov Med, 2010 Jul 31; 10(50). PMID: 20670599    Free PMC article.
Strategies for cancer vaccine development.
Matteo Vergati, Chiara Intrivici, +2 authors, Kwong Y Tsang.
J Biomed Biotechnol, 2010 Aug 14; 2010. PMID: 20706612    Free PMC article.
Improved endpoints for cancer immunotherapy trials.
Axel Hoos, Alexander M M Eggermont, +7 authors, Jedd Wolchok.
J Natl Cancer Inst, 2010 Sep 10; 102(18). PMID: 20826737    Free PMC article.
Highly Cited. Review.
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
Yolanda Nesbeth, Jose R Conejo-Garcia.
Clin Dev Immunol, 2010 Nov 16; 2010. PMID: 21076522    Free PMC article.
Immunotherapy for ovarian cancer: what's next?
Lana E Kandalaft, Daniel J Powell, Nathan Singh, George Coukos.
J Clin Oncol, 2010 Nov 17; 29(7). PMID: 21079136    Free PMC article.
Active immunotherapy induces antibody responses that target tumor angiogenesis.
Jonathan Schoenfeld, Masahisa Jinushi, +7 authors, Glenn Dranoff.
Cancer Res, 2010 Dec 17; 70(24). PMID: 21159637    Free PMC article.
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
Ahmad Tarhini, Ernest Lo, David R Minor.
Cancer Biother Radiopharm, 2011 Jan 06; 25(6). PMID: 21204754    Free PMC article.
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
Hélène Bour-Jordan, Jonathan H Esensten, +3 authors, Jeffrey A Bluestone.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488898    Free PMC article.
Highly Cited. Review.
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang, Jason Jalil, +10 authors, Antoni Ribas.
Clin Cancer Res, 2011 May 12; 17(12). PMID: 21558401    Free PMC article.
Prostate cancer immunotherapy.
Kenneth F May, James L Gulley, +2 authors, Philip W Kantoff.
Clin Cancer Res, 2011 Jun 28; 17(16). PMID: 21700764    Free PMC article.
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
Gina M Mantia-Smaldone, Robert P Edwards, Anda M Vlad.
Cancer Manag Res, 2011 Jul 08; 3. PMID: 21734812    Free PMC article.
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Andrea R Hagemann, Ian S Hagemann, +11 authors, George Coukos.
Cancer Biol Ther, 2011 Jul 26; 12(4). PMID: 21785280    Free PMC article.
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Jianda Yuan, Matthew Adamow, +16 authors, Sacha Gnjatic.
Proc Natl Acad Sci U S A, 2011 Sep 22; 108(40). PMID: 21933959    Free PMC article.
Highly Cited.
Rethinking ovarian cancer: recommendations for improving outcomes.
Sebastian Vaughan, Jermaine I Coward, +23 authors, Frances R Balkwill.
Nat Rev Cancer, 2011 Sep 24; 11(10). PMID: 21941283    Free PMC article.
Highly Cited.
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
Scott K Pruitt, David Boczkowski, +5 authors, Smita Nair.
Eur J Immunol, 2011 Oct 27; 41(12). PMID: 22028176    Free PMC article.
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
Gérald E Piérard, François Aubin, Philippe Humbert.
Dermatol Res Pract, 2011 Nov 03; 2012. PMID: 22046181    Free PMC article.
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Xiang-Yang Wang, Daming Zuo, Devanand Sarkar, Paul B Fisher.
Expert Opin Pharmacother, 2011 Nov 15; 12(17). PMID: 22077831    Free PMC article.
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Rebecca Waitz, Stephen B Solomon, +4 authors, James P Allison.
Cancer Res, 2011 Nov 24; 72(2). PMID: 22108823    Free PMC article.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
Experimental mouse tumour models: what can be learnt about human cancer immunology?
Glenn Dranoff.
Nat Rev Immunol, 2011 Dec 03; 12(1). PMID: 22134155
New challenges in endpoints for drug development in advanced melanoma.
Antoni Ribas, Peter Hersey, +4 authors, John M Kirkwood.
Clin Cancer Res, 2011 Dec 07; 18(2). PMID: 22142824    Free PMC article.
Defining the critical hurdles in cancer immunotherapy.
Bernard A Fox, Dolores J Schendel, +102 authors, Mary L Disis.
J Transl Med, 2011 Dec 16; 9. PMID: 22168571    Free PMC article.
Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff.
Nature, 2011 Dec 24; 480(7378). PMID: 22193102    Free PMC article.
Highly Cited. Review.
Quantitative monitoring of mouse lung tumors by magnetic resonance imaging.
Alexander Sasha Krupnick, Vanessa K Tidwell, +7 authors, Joel R Garbow.
Nat Protoc, 2012 Jan 10; 7(1). PMID: 22222788    Free PMC article.
Current status of immunotherapy for the treatment of lung cancer.
Sanjay Murala, Vamsi Alli, +2 authors, Alexander S Krupnick.
J Thorac Dis, 2012 Jan 21; 2(4). PMID: 22263052    Free PMC article.
Intensifying tumour immunity through combination therapy.
Glenn Dranoff.
Lancet Oncol, 2012 Feb 14; 13(5). PMID: 22326921    Free PMC article.
Combining immunotherapy and targeted therapies in cancer treatment.
Matthew Vanneman, Glenn Dranoff.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437869    Free PMC article.
Highly Cited. Review.
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST.
Mizuki Nishino, Jyothi P Jagannathan, +4 authors, Nikhil H Ramaiya.
AJR Am J Roentgenol, 2012 Mar 28; 198(4). PMID: 22451534    Free PMC article.
Highly Cited. Review.
Regulatory T cells in human ovarian cancer.
Dong-Jun Peng, Rebecca Liu, Weiping Zou.
J Oncol, 2012 Apr 07; 2012. PMID: 22481922    Free PMC article.
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.
Florencia Paula Madorsky-Rowdo, María Laura Lacreu, José Mordoh.
Front Immunol, 2012 May 09; 3. PMID: 22566975    Free PMC article.
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Pankaj Agarwalla, Zachary Barnard, +2 authors, William T Curry.
J Immunother, 2012 May 12; 35(5). PMID: 22576343    Free PMC article.
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.
Susan R Slovin.
Front Oncol, 2012 Jun 05; 2. PMID: 22662316    Free PMC article.
Revisiting the role of T cells in tumor regression.
Nadège Bercovici, Alain Trautmann.
Oncoimmunology, 2012 Jun 28; 1(3). PMID: 22737611    Free PMC article.
Immunotherapy in ovarian cancer.
Gina M Mantia-Smaldone, Bradley Corr, Christina S Chu.
Hum Vaccin Immunother, 2012 Aug 22; 8(9). PMID: 22906947    Free PMC article.
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Geoffrey R Oxnard, Michael J Morris, +4 authors, Lawrence H Schwartz.
J Natl Cancer Inst, 2012 Aug 29; 104(20). PMID: 22927506    Free PMC article.
Influence of human immune cells on cancer: studies at the University of Colorado.
Tullia C Bruno, Jena D French, +7 authors, Jill E Slansky.
Immunol Res, 2012 Sep 04; 55(1-3). PMID: 22941561    Free PMC article.
The price of immunity.
Romina S Goldszmid, Giorgio Trinchieri.
Nat Immunol, 2012 Sep 20; 13(10). PMID: 22990891
Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Sofie Wilgenhof, Stephanie Du Four, Hendrik Everaert, Bart Neyns.
Cancer Invest, 2012 Oct 10; 30(10). PMID: 23043499    Free PMC article.
Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration.
Hoon Kyu Oh, Jeong-Im Sin, +3 authors, Youn Seok Choi.
J Gynecol Oncol, 2012 Oct 25; 23(4). PMID: 23094131    Free PMC article.
Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes.
Yoshiki Shigematsu, Takeshi Hanagiri, +8 authors, Fumihiro Tanaka.
Oncol Lett, 2012 Dec 04; 4(4). PMID: 23205074    Free PMC article.
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.
José I Quetglas, Liza B John, +4 authors, Cristian Smerdou.
Oncoimmunology, 2012 Dec 18; 1(8). PMID: 23243597    Free PMC article.
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Margaret K Callahan, Michael A Postow, Jedd D Wolchok.
Clin Dermatol, 2013 Feb 27; 31(2). PMID: 23438382    Free PMC article.
Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.
Omar A Ali, Edward Doherty, David J Mooney, Dwaine Emerich.
Biomatter, 2011 Jul 01; 1(1). PMID: 23507728    Free PMC article.
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S F Slovin, C S Higano, +8 authors, T M Beer.
Ann Oncol, 2013 Mar 29; 24(7). PMID: 23535954    Free PMC article.
Highly Cited.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy, Karen M Kaluza, Gordon J Freeman, George Coukos.
Cancer Res, 2013 May 02; 73(12). PMID: 23633484    Free PMC article.
Highly Cited.
Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.
Georg Feldmann, Peter Brossart, Matthias Zipfel, Marie von Lilienfeld-Toal.
Case Rep Oncol, 2013 May 21; 6(1). PMID: 23687494    Free PMC article.
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma.
Taylor J Brueseke, Krishnansu S Tewari.
Clin Pharmacol, 2013 Jun 01; 5. PMID: 23723721    Free PMC article.
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
Mizuki Nishino, Anita Giobbie-Hurder, +3 authors, F Stephen Hodi.
Clin Cancer Res, 2013 Jun 08; 19(14). PMID: 23743568    Free PMC article.
Highly Cited.
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.
D Hannani, C Locher, +9 authors, L Zitvogel.
Cell Death Differ, 2013 Jun 08; 21(1). PMID: 23744294    Free PMC article.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.
Vincent Lavoué, Aurélie Thédrez, +6 authors, Florian Cabillic.
J Transl Med, 2013 Jun 15; 11. PMID: 23763830    Free PMC article.
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
Lana E Kandalaft, Cheryl L Chiang, +4 authors, George Coukos.
J Transl Med, 2013 Jun 20; 11. PMID: 23777306    Free PMC article.
ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells.
Julien Faget, Vanja Sisirak, +3 authors, Christine Ménétrier-Caux.
Oncoimmunology, 2013 Jun 27; 2(3). PMID: 23802069    Free PMC article.
Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H Manjili, +3 authors, Xiang-Yang Wang.
Adv Cancer Res, 2013 Jul 23; 119. PMID: 23870514    Free PMC article.
Highly Cited. Review.
Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Masanori Kobayashi, Tomoyo Sakabe, +15 authors, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT).
J Gastrointest Surg, 2013 Jul 24; 17(9). PMID: 23877328
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Jaikumar Duraiswamy, Gordon J Freeman, George Coukos.
Cancer Res, 2013 Aug 27; 73(23). PMID: 23975756    Free PMC article.
Highly Cited.
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.
Brynn B Duncan, Steven L Highfill, +12 authors, Terry J Fry.
J Immunother, 2013 Sep 03; 36(8). PMID: 23994886    Free PMC article.
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
Ben C Creelan, Scott Antonia, +8 authors, Alberto Chiappori.
J Immunother, 2013 Sep 03; 36(8). PMID: 23994887    Free PMC article.
Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.
Pedro C Rodriguez, Belinda Sanchez.
Curr Top Med Chem, 2013 Sep 27; 13(20). PMID: 24066886    Free PMC article.
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.
Giulio Tosti, Emilia Cocorocchio, Elisabetta Pennacchioli.
Clin Cosmet Investig Dermatol, 2013 Nov 10; 6. PMID: 24204168    Free PMC article.
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre Van der Bruggen.
Cancers (Basel), 2011 Jan 01; 3(3). PMID: 24212939    Free PMC article.
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
Margaret K Callahan, Gregg Masters, +13 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 15; 2(1). PMID: 24416731    Free PMC article.
Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.
Stephanie K Dougan, Michael Dougan, +6 authors, Hidde L Ploegh.
Cancer Immunol Res, 2014 Jan 25; 1(2). PMID: 24459675    Free PMC article.
Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.
J Saison, T Ferry, +8 authors, Lyon HIV Cohort Study.
Clin Exp Immunol, 2014 Jan 28; 176(3). PMID: 24460818    Free PMC article.
Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Omar A Ali, Catia Verbeke, +6 authors, David J Mooney.
Cancer Res, 2014 Feb 01; 74(6). PMID: 24480625    Free PMC article.
Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.
Jason J Luke, Cecilia Lezcano, F Stephen Hodi, George F Murphy.
J Clin Oncol, 2014 Mar 13; 33(6). PMID: 24616309    Free PMC article.
Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction.
Jing-Yi Zhao, Xue-Lei Ma, +7 authors, Yu-Quan Wei.
Clin Exp Med, 2014 Mar 13; 15(2). PMID: 24619299
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Jenessa B Smith, Caitlin Stashwick, Daniel J Powell.
Gynecol Oncol, 2014 Mar 25; 134(1). PMID: 24657487    Free PMC article.
Getting personal with neoantigen-based therapeutic cancer vaccines.
Nir Hacohen, Edward F Fritsch, +2 authors, Catherine J Wu.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777245    Free PMC article.
Highly Cited.
Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.
Diana A Alvarez Arias, Hye-Jung Kim, +4 authors, Harvey Cantor.
Cancer Immunol Res, 2014 Apr 30; 2(3). PMID: 24778317    Free PMC article.
Gut microbiota and the paradox of cancer immunotherapy.
Theofilos Poutahidis, Markus Kleinewietfeld, Susan E Erdman.
Front Immunol, 2014 Apr 30; 5. PMID: 24778636    Free PMC article.
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown, Rene L Warren, +4 authors, Robert A Holt.
Genome Res, 2014 May 02; 24(5). PMID: 24782321    Free PMC article.
Highly Cited.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Donald Lawrence, +20 authors, David McDermott.
Cancer Immunol Res, 2014 May 20; 2(7). PMID: 24838938    Free PMC article.
Highly Cited.
Immunotherapy in the treatment of non-small cell lung cancer.
Raghav Sundar, Richie Soong, +2 authors, Ross A Soo.
Lung Cancer, 2014 Jun 02; 85(2). PMID: 24880938    Free PMC article.
Pathogen-sensing and regulatory T cells: integrated regulators of immune responses.
William E Paul, Zvi Grossman.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894087    Free PMC article.
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Eric R Lutz, Annie A Wu, +14 authors, Lei Zheng.
Cancer Immunol Res, 2014 Jun 20; 2(7). PMID: 24942756    Free PMC article.
Highly Cited.
[Advances of immunotherapy in small cell lung cancer].
Jingjing Liu, Shuang Zhang, Hui Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2014 Jun 21; 17(6). PMID: 24949688    Free PMC article.
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
Mizuki Nishino, Maria Gargano, +2 authors, F Stephen Hodi.
J Immunother Cancer, 2014 Jul 06; 2. PMID: 24991412    Free PMC article.
Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
T Du, G Shi, +5 authors, D C Yu.
Cancer Gene Ther, 2014 Jul 19; 21(8). PMID: 25034886
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Antonio M Grimaldi, Ester Simeone, +15 authors, Paolo A Ascierto.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083318    Free PMC article.
Highly Cited.
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.
Xiao-Dong Li, Mei Ji, +5 authors, Jing-Ting Jiang.
J Transl Med, 2014 Aug 13; 12. PMID: 25113800    Free PMC article.
Hydrogels and scaffolds for immunomodulation.
Ankur Singh, Nicholas A Peppas.
Adv Mater, 2014 Aug 27; 26(38). PMID: 25155610    Free PMC article.
One patient, two lesions, two oncogenic drivers of gastric cancer.
Clara Alsinet, Marco Ranzani, David J Adams.
Genome Biol, 2014 Sep 16; 15(8). PMID: 25222187    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Pilot study of p62 DNA vaccine in dogs with mammary tumors.
Vladimir Gabai, Franco M Venanzi, +11 authors, Alexander Shneider.
Oncotarget, 2014 Oct 10; 5(24). PMID: 25296974    Free PMC article.
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
Masanori Kobayashi, Asako Chiba, +8 authors, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT).
J Ovarian Res, 2014 Oct 10; 7. PMID: 25298213    Free PMC article.
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Limo Chen, Don L Gibbons, +27 authors, F Xiao-Feng Qin.
Nat Commun, 2014 Oct 29; 5. PMID: 25348003    Free PMC article.
Highly Cited.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F Stephen Hodi, Sandra Lee, +7 authors, John M Kirkwood.
JAMA, 2014 Nov 05; 312(17). PMID: 25369488    Free PMC article.
Highly Cited.
Checkpoint inhibitors in immunotherapy of ovarian cancer.
Dong-hui Wang, Liang Guo, Xiao-hua Wu.
Tumour Biol, 2014 Nov 21; 36(1). PMID: 25409618
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Dalil Hannani, Marie Vétizou, +30 authors, Laurence Zitvogel.
Cell Res, 2015 Jan 15; 25(2). PMID: 25582080    Free PMC article.
Highly Cited.
The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Tasha Hughes, Matthew Klairmont, +3 authors, Howard L Kaufman.
Cancer Immunol Immunother, 2015 Jan 22; 64(4). PMID: 25603775    Free PMC article.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
Immunotherapeutic approaches to ovarian cancer treatment.
Cariad Chester, Oliver Dorigo, Jonathan S Berek, Holbrook Kohrt.
J Immunother Cancer, 2015 Mar 26; 3. PMID: 25806106    Free PMC article.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell.
Cancer Biol Ther, 2015 Apr 22; 16(6). PMID: 25894333    Free PMC article.
Highly Cited. Review.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Molecular staging of gynecological cancer: What is the future?
Pratibha S Binder, Jaime Prat, David G Mutch.
Best Pract Res Clin Obstet Gynaecol, 2015 May 03; 29(6). PMID: 25934522    Free PMC article.
The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.
Haoqing Shi, Xiangjie Qi, +4 authors, Haitao Niu.
Chin J Cancer Res, 2015 May 06; 27(2). PMID: 25937774    Free PMC article.
Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.
Katelyn T Byrne, Robert H Vonderheide, Elizabeth M Jaffee, Todd D Armstrong.
Cancer Immunol Res, 2015 May 15; 3(6). PMID: 25968457    Free PMC article.
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
Hina Khan, Rasim Gucalp, Iuliana Shapira.
J Oncol, 2015 Jun 11; 2015. PMID: 26060497    Free PMC article.
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Tomoe Higuchi, Dallas B Flies, +4 authors, Sarah F Adams.
Cancer Immunol Res, 2015 Jul 04; 3(11). PMID: 26138335    Free PMC article.
Highly Cited.
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
Evan J Lipson, William H Sharfman, +12 authors, Suzanne L Topalian.
J Transl Med, 2015 Jul 06; 13. PMID: 26143264    Free PMC article.
Clinical Development of Immune Checkpoint Inhibitors.
Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161407    Free PMC article.
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.
Maria Libera Ascierto, Ignacio Melero, Paolo Antonio Ascierto.
Front Oncol, 2015 Jul 29; 5. PMID: 26217587    Free PMC article.
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Zhiqiang Guo, Haolin Wang, +2 authors, Shulan Zhang.
J Transl Med, 2015 Jul 30; 13. PMID: 26219551    Free PMC article.
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
Francesca De Felice, Claudia Marchetti, +4 authors, Pierluigi Benedetti Panici.
J Immunol Res, 2015 Aug 04; 2015. PMID: 26236750    Free PMC article.
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
A E Rice, Y E Latchman, +3 authors, F R Jones.
Cancer Gene Ther, 2015 Sep 05; 22(9). PMID: 26337747
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.
Giorgio Parmiani, Cristina Maccalli, Michele Maio.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343195    Free PMC article.
Overexpression of CD45RA isoforms in carriers of the C77G mutation leads to hyporeactivity of CD4+CD25highFoxp3+ regulatory T cells.
C Pokoyski, T Lienen, +4 authors, R Schwinzer.
Genes Immun, 2015 Sep 12; 16(8). PMID: 26355564
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Zeynep Eroglu, Dae Won Kim, +9 authors, Antoni Ribas.
Eur J Cancer, 2015 Sep 15; 51(17). PMID: 26364516    Free PMC article.
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
Lijo John, C Lance Cowey.
Dermatol Ther (Heidelb), 2015 Sep 21; 5(3). PMID: 26387031    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.
David A Reardon, Mark R Gilbert, Wolfgang Wick, Linda Liau.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516225    Free PMC article.
HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells.
Haiyan Xiao, Jing Jiao, +11 authors, Ulf H Beier.
Int J Cancer, 2015 Dec 26; 138(10). PMID: 26704363    Free PMC article.
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
L Marthey, C Mateus, +16 authors, F Carbonnel.
J Crohns Colitis, 2016 Jan 20; 10(4). PMID: 26783344    Free PMC article.
Highly Cited.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.
Ariel Bulua Bourla, Dmitriy Zamarin.
Oncology (Williston Park), 2016 Jan 23; 30(1). PMID: 26791846    Free PMC article.
Targeting the tumour microenvironment in ovarian cancer.
Jean M Hansen, Robert L Coleman, Anil K Sood.
Eur J Cancer, 2016 Feb 06; 56. PMID: 26849037    Free PMC article.
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
William T Curry, Ramana Gorrepati, +9 authors, Glenn Dranoff.
Clin Cancer Res, 2016 Feb 14; 22(12). PMID: 26873960    Free PMC article.
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Axel Hoos.
Nat Rev Drug Discov, 2016 Mar 12; 15(4). PMID: 26965203
Highly Cited.
A primer on tumour immunology and prostate cancer immunotherapy.
Runhan Ren, Madhuri Koti, +5 authors, D Robert Siemens.
Can Urol Assoc J, 2016 Mar 16; 10(1-2). PMID: 26977209    Free PMC article.
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Dmitriy Zamarin, Amir A Jazaeri.
Gynecol Oncol, 2016 Mar 27; 141(1). PMID: 27016233    Free PMC article.
Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?
Amol Mehta, Rahmi Oklu, Rahul A Sheth.
Gastroenterol Res Pract, 2016 Apr 07; 2016. PMID: 27051417    Free PMC article.
SHP-1: the next checkpoint target for cancer immunotherapy?
H Angharad Watson, Sophie Wehenkel, James Matthews, Ann Ager.
Biochem Soc Trans, 2016 Apr 14; 44(2). PMID: 27068940    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
Rajitha Lokadasan, Francis V James, Geetha Narayanan, Pranab K Prabhakaran.
Ecancermedicalscience, 2016 Apr 26; 10. PMID: 27110282    Free PMC article.
A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.
Jinxu Fang, Biliang Hu, +3 authors, Pin Wang.
Mol Ther Oncolytics, 2016 Apr 28; 3. PMID: 27119119    Free PMC article.
Opportunities in immunotherapy of ovarian cancer.
G Coukos, J Tanyi, L E Kandalaft.
Ann Oncol, 2016 May 04; 27 Suppl 1. PMID: 27141063    Free PMC article.
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
De-Kuan Chang, Eric Peterson, +6 authors, Wayne A Marasco.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141347    Free PMC article.
Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?
Örjan Strannegård, Fredrik B Thorén.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141351    Free PMC article.
Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy.
Li-Sheng Chang, Wan-Lun Yan, +4 authors, Shih-Jen Liu.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141356    Free PMC article.
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Jon Bjoern, Nikolaj Juul Nitschke, +3 authors, Inge Marie Svane.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141381    Free PMC article.
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
Michael D Iglesia, Joel S Parker, +3 authors, Benjamin G Vincent.
J Natl Cancer Inst, 2016 Jun 24; 108(11). PMID: 27335052    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Gloria Mittica, Sofia Genta, Massimo Aglietta, Giorgio Valabrega.
Int J Mol Sci, 2016 Jul 23; 17(7). PMID: 27447625    Free PMC article.
Therapeutic targets and new directions for antibodies developed for ovarian cancer.
Heather J Bax, Debra H Josephs, +3 authors, Sophia N Karagiannis.
MAbs, 2016 Oct 30; 8(8). PMID: 27494775    Free PMC article.
Circulating protein and antibody biomarker for personalized cancer immunotherapy.
Jianda Yuan.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532021    Free PMC article.
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.
Viktor H Koelzer, Tobias Buser, +6 authors, Kirsten D Mertz.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532022    Free PMC article.
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Heather L McArthur, Adi Diab, +27 authors, Larry Norton.
Clin Cancer Res, 2016 Nov 05; 22(23). PMID: 27566765    Free PMC article.
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Roch Houot, Philippe Gaulard, +18 authors, Daniel Olive.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622041    Free PMC article.
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
Xiao X Wei, Stephen Chan, +13 authors, Lawrence Fong.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27688020    Free PMC article.
Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis.
Edurne Arriola, Matthew Wheater, +2 authors, Christian Ottensmeier.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757302    Free PMC article.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
Regulatory T cells in cancer immunotherapy.
Atsushi Tanaka, Shimon Sakaguchi.
Cell Res, 2016 Dec 21; 27(1). PMID: 27995907    Free PMC article.
Highly Cited. Review.
Update on immune checkpoint inhibitors in gynecological cancers.
Valerie Heong, Natalie Ngoi, David Shao Peng Tan.
J Gynecol Oncol, 2016 Dec 29; 28(2). PMID: 28028993    Free PMC article.
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Franck Carbonnel, Emilie Soularue, +4 authors, Caroline Robert.
Semin Immunopathol, 2017 Jan 18; 39(3). PMID: 28093620
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu.
Nat Rev Clin Oncol, 2017 Jan 18; 14(6). PMID: 28094262
Highly Cited. Review.
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.
Thomas Worzfeld, Elke Pogge von Strandmann, +4 authors, Rolf Müller.
Front Oncol, 2017 Mar 10; 7. PMID: 28275576    Free PMC article.
Highly Cited. Review.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Frederick Arce Vargas, Andrew J S Furness, +29 authors, Sergio A Quezada.
Immunity, 2017 Apr 16; 46(4). PMID: 28410988    Free PMC article.
Highly Cited.
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.
Stefanie Gross, Michael Erdmann, +12 authors, Beatrice Schuler-Thurner.
JCI Insight, 2017 Apr 20; 2(8). PMID: 28422751    Free PMC article.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Upendra P Hegde, Bijay Mukherji.
Cancer Immunol Immunother, 2017 May 13; 66(9). PMID: 28497159    Free PMC article.
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Silvia Martin Lluesma, Anita Wolfer, Alexandre Harari, Lana E Kandalaft.
Biomedicines, 2017 May 26; 4(2). PMID: 28536377    Free PMC article.
Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.
Eiichi Ishikawa, Tetsuya Yamamoto, Akira Matsumura.
Neurol Med Chir (Tokyo), 2017 May 26; 57(7). PMID: 28539528    Free PMC article.
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
Georgina V Long, Jeffrey S Weber, +12 authors, Jedd D Wolchok.
JAMA Oncol, 2017 Jul 01; 3(11). PMID: 28662232    Free PMC article.
Highly Cited.
Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.
Baodan Yu, Junli Wang, +8 authors, Jun Xu.
Exp Ther Med, 2017 Jul 05; 14(1). PMID: 28673007    Free PMC article.
Immune Checkpoint Blockers and Ovarian Cancer.
Chinmoy K Bose.
Indian J Med Paediatr Oncol, 2017 Sep 14; 38(2). PMID: 28900328    Free PMC article.
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Nusrat Jahan, Hammad Talat, William T Curry.
Neuro Oncol, 2017 Oct 11; 20(1). PMID: 29016879    Free PMC article.
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Tamson Moore, Courtney Regan Wagner, +23 authors, Michael I Nishimura.
Cancer Immunol Immunother, 2017 Oct 21; 67(2). PMID: 29052782    Free PMC article.
The immunopeptidomic landscape of ovarian carcinomas.
Heiko Schuster, Janet K Peper, +21 authors, Philipp Wagner.
Proc Natl Acad Sci U S A, 2017 Nov 03; 114(46). PMID: 29093164    Free PMC article.
Highly Cited.
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
Hoda Anwar, Christos Sachpekidis, +4 authors, Antonia Dimitrakopoulou-Strauss.
Eur J Nucl Med Mol Imaging, 2017 Nov 11; 45(3). PMID: 29124281
Immune-related tumour response assessment criteria: a comprehensive review.
Bhanusupriya Somarouthu, Susanna I Lee, +3 authors, Avinash Kambadakone.
Br J Radiol, 2017 Nov 28; 91(1084). PMID: 29172675    Free PMC article.
Management of intracranial melanomas in the era of precision medicine.
Grace J Young, Wenya Linda Bi, +3 authors, Ian F Dunn.
Oncotarget, 2017 Nov 29; 8(51). PMID: 29179523    Free PMC article.
Immune checkpoints, their control by immunotherapy and ovarian cancer.
Chinmoy K Bose.
Contemp Oncol (Pozn), 2017 Nov 29; 21(3). PMID: 29180924    Free PMC article.
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.
Christina H Son, Gini F Fleming, John W Moroney.
Cancer Manag Res, 2017 Dec 01; 9. PMID: 29184441    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
Shoko Nakayama, Taiji Yokote, +10 authors, Motomu Tsuji.
Blood Adv, 2018 Jan 04; 1(8). PMID: 29296965    Free PMC article.
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Nicola R Hardwick, Paul Frankel, +13 authors, Mihaela Cristea.
Clin Cancer Res, 2018 Jan 06; 24(6). PMID: 29301826    Free PMC article.
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Stefan Schliep, Abbas Agaimy, +3 authors, Lucie Heinzerling.
J Immunother Cancer, 2018 Jan 16; 6(1). PMID: 29332608    Free PMC article.
Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.
B L Adler, M K Pezhouh, +15 authors, R A Anders.
J Intern Med, 2018 Feb 22; 283(6). PMID: 29464806    Free PMC article.
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Georgia Ritchie, Harry Gasper, +4 authors, Chee Khoon Lee.
JAMA Oncol, 2018 Feb 23; 4(4). PMID: 29470579    Free PMC article.
Systematic Review.
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
Christos Sachpekidis, Hoda Anwar, +5 authors, Antonia Dimitrakopoulou-Strauss.
Eur J Nucl Med Mol Imaging, 2018 Feb 27; 45(8). PMID: 29478079
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Antje Tunger, Maximilian Kießler, +4 authors, Marc Schmitz.
Biomedicines, 2018 Mar 02; 6(1). PMID: 29494517    Free PMC article.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, +15 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2018 Mar 28; 115(15). PMID: 29581255    Free PMC article.
Highly Cited.
Dendritic Cell-Based Immunotherapy for Solid Tumors.
Nam-Chul Jung, Jun-Ho Lee, +2 authors, Dae-Seog Lim.
Transl Oncol, 2018 Apr 09; 11(3). PMID: 29627706    Free PMC article.
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.
Xichen Zheng, Zhaoxu Fang, +17 authors, Yuhui Huang.
J Clin Invest, 2018 Apr 18; 128(5). PMID: 29664018    Free PMC article.
Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells.
Sonja Lieber, Silke Reinartz, +8 authors, Magdalena Huber.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721385    Free PMC article.
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Remy Thomas, Ghaneya Al-Khadairi, +4 authors, Julie Decock.
Front Immunol, 2018 May 18; 9. PMID: 29770138    Free PMC article.
Highly Cited. Review.
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, +7 authors, Patrick J Stiff.
J Ovarian Res, 2018 May 31; 11(1). PMID: 29843813    Free PMC article.
The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Galaxia M Rodriguez, Kristianne J C Galpin, Curtis W McCloskey, Barbara C Vanderhyden.
Cancers (Basel), 2018 Jul 26; 10(8). PMID: 30042343    Free PMC article.
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Christine A Garcia, Alex El-Ali, +4 authors, Diwakar Davar.
J Immunother Cancer, 2018 Sep 02; 6(1). PMID: 30170622    Free PMC article.
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.
Francesco Tovoli, Matteo Renzulli, +2 authors, Luigi Bolondi.
Hepat Oncol, 2018 Sep 08; 4(4). PMID: 30191059    Free PMC article.
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Ying L Liu, Dmitriy Zamarin.
Curr Oncol Rep, 2018 Nov 14; 20(12). PMID: 30421009    Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Magnus Pedersen, Marie Christine Wulff Westergaard, +14 authors, Inge Marie Svane.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524900    Free PMC article.
Severe tracheal stenosis after first administration of pembrolizumab rescued by Dumon Y-stent in a lung cancer patient.
Daisuke Himeji, Gen-Ichi Tanaka, +4 authors, Kousuke Marutsuka.
Respir Med Case Rep, 2019 Aug 28; 28. PMID: 31453084    Free PMC article.
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.
Nicholas Gravbrot, Katalin Scherer, Srinath Sundararajan.
Case Rep Oncol Med, 2019 Dec 31; 2019. PMID: 31885974    Free PMC article.
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.
Mikhail Binnewies, Adriana M Mujal, +15 authors, Matthew F Krummel.
Cell, 2019 Apr 09; 177(3). PMID: 30955881    Free PMC article.
Highly Cited.
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Nicolas Huyghe, Paméla Baldin, Marc Van den Eynde.
Gastroenterol Rep (Oxf), 2020 Feb 28; 8(1). PMID: 32104582    Free PMC article.
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Qingyang Xiao, André Nobre, +5 authors, Isabel Barragán.
J Clin Med, 2020 Jan 24; 9(1). PMID: 31968651    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors: recent progress and potential biomarkers.
Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord.
Exp Mol Med, 2018 Dec 14; 50(12). PMID: 30546008    Free PMC article.
Highly Cited. Review.
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M Rizk, Robyn D Gartrell, +4 authors, Yvonne M Saenger.
Hematol Oncol Clin North Am, 2019 Mar 06; 33(2). PMID: 30833001    Free PMC article.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.
Andrew P Wright, Marc S Piper, Shrinivas Bishu, Ryan W Stidham.
Aliment Pharmacol Ther, 2019 Apr 30; 49(12). PMID: 31035308    Free PMC article.
Systematic Review.
Emerging therapies for small cell lung cancer.
Sen Yang, Zhe Zhang, Qiming Wang.
J Hematol Oncol, 2019 May 03; 12(1). PMID: 31046803    Free PMC article.
Highly Cited. Review.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy.
Saurabh K Garg, Matthew J Ott, +12 authors, Joseph Markowitz.
Front Immunol, 2020 Mar 13; 11. PMID: 32161584    Free PMC article.
Mechanisms of human FoxP3+ Treg cell development and function in health and disease.
M Attias, T Al-Aubodah, C A Piccirillo.
Clin Exp Immunol, 2019 Mar 14; 197(1). PMID: 30864147    Free PMC article.
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Ioana Plesca, Antje Tunger, +6 authors, Marc Schmitz.
Front Immunol, 2020 Mar 21; 11. PMID: 32194568    Free PMC article.
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology.
Paul David, Malgorzata Drabczyk-Pluta, +24 authors, Gennadiy Zelinskyy.
PLoS Pathog, 2020 Apr 01; 16(3). PMID: 32226027    Free PMC article.
A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer.
Qi Ding, Shanshan Dong, +10 authors, Yong Zeng.
Aging (Albany NY), 2020 Mar 26; 12(6). PMID: 32208363    Free PMC article.
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Sarah Nersesian, Haley Glazebrook, +2 authors, Jeanette E Boudreau.
Front Immunol, 2019 Aug 29; 10. PMID: 31456796    Free PMC article.
Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.
A Charlotte M T de Wolf, Carla A Herberts, Marcel H N Hoefnagel.
Front Med (Lausanne), 2020 Apr 18; 7. PMID: 32300597    Free PMC article.
Systematic Review.
Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas.
Karl-Frederick Karstens, Jan Kempski, +8 authors, Penelope Pelczar.
PLoS One, 2020 Apr 17; 15(4). PMID: 32298379    Free PMC article.
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Christina A Hartl, Adrian Bertschi, +5 authors, Michael S Goldberg.
J Immunother Cancer, 2019 Aug 01; 7(1). PMID: 31362778    Free PMC article.
Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials.
Aman Chauhan, Tanvir Kabir, +3 authors, Charles A Kunos.
Oncotarget, 2020 May 05; 11(16). PMID: 32363000    Free PMC article.
Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.
Yukihiro Umeda, Miwa Morikawa, +8 authors, Tamotsu Ishizuka.
J Immunother Cancer, 2020 Apr 30; 8(1). PMID: 32345624    Free PMC article.
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.
Filippo Galli, Jesus Vera Aguilera, +3 authors, Alberto Signore.
J Exp Clin Cancer Res, 2020 May 20; 39(1). PMID: 32423420    Free PMC article.
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Donastas Sakellariou-Thompson, Marie-Andrée Forget, +5 authors, Chantale Bernatchez.
Cancer Immunol Immunother, 2019 Oct 12; 68(11). PMID: 31602489    Free PMC article.
Ovarian cancer.
Ursula A Matulonis, Anil K Sood, +3 authors, Beth Y Karlan.
Nat Rev Dis Primers, 2016 Aug 26; 2. PMID: 27558151    Free PMC article.
Highly Cited. Review.
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.
Colin G Buss, Sangeeta N Bhatia.
Proc Natl Acad Sci U S A, 2020 Jun 05; 117(24). PMID: 32493746    Free PMC article.
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Innocenza Palaia, Federica Tomao, +2 authors, Pierluigi Benedetti Panici.
Onco Targets Ther, 2020 Jul 04; 13. PMID: 32617007    Free PMC article.
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy.
Christopher A Chuckran, Chang Liu, +2 authors, Dario Aa Vignali.
J Immunother Cancer, 2020 Jul 18; 8(2). PMID: 32675311    Free PMC article.
Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Sharareh Siamakpour-Reihani, Lauren Patterson Cobb, +5 authors, Angeles Alvarez Secord.
Gynecol Oncol, 2020 Jan 11; 156(3). PMID: 31918995    Free PMC article.
PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
Girija Goyal, Karrie Wong, +4 authors, Glenn Dranoff.
Cancer Immunol Res, 2018 Apr 20; 6(6). PMID: 29669721    Free PMC article.
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
Julia L Boland, Qin Zhou, +8 authors, Karen A Cadoo.
Gynecol Oncol, 2020 Jun 09; 158(2). PMID: 32507515    Free PMC article.
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer.
Alejandra Martinez, Jean-Pierre Delord, Maha Ayyoub, Christel Devaud.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32630708    Free PMC article.
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
Yanfei Yang, Yang Yang, +2 authors, Xiawei Wei.
Front Cell Dev Biol, 2020 Aug 28; 8. PMID: 32850861    Free PMC article.
Human regulatory T cells (Treg) and their response to cancer.
Theresa L Whiteside.
Expert Rev Precis Med Drug Dev, 2019 Jan 01; 4(4). PMID: 32953989    Free PMC article.
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
Guyu Zhang, Chongdong Liu, +3 authors, Zhengyu Zhang.
Oncol Lett, 2019 Mar 12; 17(3). PMID: 30854033    Free PMC article.
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence.
Mathieu Sinigaglia, Tarek Assi, +8 authors, Laurent Dercle.
EJNMMI Res, 2019 Aug 23; 9(1). PMID: 31432278    Free PMC article.
Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
Matthew J O'Shaughnessy, Katie S Murray, +8 authors, Jonathan A Coleman.
Clin Cancer Res, 2017 Sep 29; 24(3). PMID: 28954788    Free PMC article.
Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines.
Naveen K Mehta, Roma V Pradhan, +8 authors, Darrell J Irvine.
Nat Biomed Eng, 2020 Jun 03; 4(6). PMID: 32483299    Free PMC article.
Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma.
Renato B Corradi, Stephen LaRosa, +7 authors, Jonathan A Coleman.
Int J Urol, 2019 Jan 20; 26(3). PMID: 30659668    Free PMC article.
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy.
Zili Gu, Candido G Da Silva, +2 authors, Luis J Cruz.
Pharmaceutics, 2020 Nov 08; 12(11). PMID: 33158166    Free PMC article.
"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.
Matthew R Buckwalter, Pramod K Srivastava.
Semin Immunol, 2008 Aug 22; 20(5). PMID: 18715801    Free PMC article.
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.
David E Gyorki, Jianda Yuan, +8 authors, Charlotte E Ariyan.
Ann Surg Oncol, 2013 May 18; 20(9). PMID: 23681603    Free PMC article.
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
J M Moskovitz, R L Ferris.
J Dent Res, 2018 Mar 01; 97(6). PMID: 29489423    Free PMC article.
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Karim Amrane, Delphine Le Goupil, +8 authors, Solène Querellou.
Medicine (Baltimore), 2019 Jul 25; 98(29). PMID: 31335691    Free PMC article.
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Alessandra Raimondi, Giovanni Randon, +4 authors, Giuseppe Procopio.
Int J Mol Sci, 2019 Sep 05; 20(17). PMID: 31480348    Free PMC article.
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
Christos Sachpekidis, Annette Kopp-Schneider, +4 authors, Antonia Dimitrakopoulou-Strauss.
Eur J Nucl Med Mol Imaging, 2020 Dec 19; 48(6). PMID: 33336264    Free PMC article.
Immunotherapy Advances for Epithelial Ovarian Cancer.
Erin G Hartnett, Julia Knight, +3 authors, Anda M Vlad.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322601    Free PMC article.
Current and future immunotherapy approaches in ovarian cancer.
Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490226    Free PMC article.
Driving Immune Responses in the Ovarian Tumor Microenvironment.
Franklin Ning, Christopher B Cole, Christina M Annunziata.
Front Oncol, 2021 Feb 02; 10. PMID: 33520713    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Isabelle Solomon, Maria Amann, +29 authors, Sergio A Quezada.
Nat Cancer, 2021 Mar 02; 1(12). PMID: 33644766    Free PMC article.
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
Jose M González-Navajas, Dengxia Denise Fan, +4 authors, Jongdae Lee.
Front Immunol, 2021 Mar 16; 12. PMID: 33717139    Free PMC article.
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.
Maria Stella Sasso, Nikolaos Mitrousis, +5 authors, Melody A Swartz.
Sci Adv, 2021 Mar 26; 7(13). PMID: 33762337    Free PMC article.
Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer.
Alice Indini, Olga Nigro, +7 authors, Giorgio Bogani.
Cancers (Basel), 2021 May 01; 13(7). PMID: 33916221    Free PMC article.
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
Luca Falzone, Giuseppa Scandurra, +5 authors, Paolo Scollo.
Int J Oncol, 2021 Jun 17; 59(1). PMID: 34132354    Free PMC article.
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma.
Diogo Garcia, Juliana Rodrigues Beal, +2 authors, Gustavo Schvartsman.
Case Rep Oncol, 2021 Jul 13; 14(2). PMID: 34248554    Free PMC article.
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Lauren S Levine, Kelly M Mahuron, +11 authors, Adil I Daud.
Ann Surg Oncol, 2020 Jun 04; 27(11). PMID: 32488521    Free PMC article.
Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.
Linping Ke, Leilei Wu, Jinming Yu, Xue Meng.
Nucl Med Commun, 2021 Apr 27; 42(9). PMID: 33899782    Free PMC article.
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Masatsugu Miyashita, Teruki Shimizu, Eishi Ashihara, Osamu Ukimura.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445615    Free PMC article.
Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency.
Lacey A Perdue, Priscilla Do, +8 authors, Erik C Dreaden.
Biomacromolecules, 2020 May 07; 21(7). PMID: 32374589    Free PMC article.
T cell receptor (TCR) signaling in health and disease.
Kinjal Shah, Amr Al-Haidari, Jianmin Sun, Julhash U Kazi.
Signal Transduct Target Ther, 2021 Dec 14; 6(1). PMID: 34897277    Free PMC article.
The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Alan J Korman, Sarah C Garrett-Thomson, Nils Lonberg.
Nat Rev Drug Discov, 2021 Dec 24;. PMID: 34937915
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.
Karen S Anderson, Timothy K Erick, +10 authors, Beth Overmoyer.
Breast Cancer Res Treat, 2022 Apr 29; 194(1). PMID: 35482127    Free PMC article.
Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Yang Zhao, Hui Xu, Mingzhi Zhang, Ling Li.
Front Genet, 2022 May 24; 13. PMID: 35601491    Free PMC article.
A vaccine targeting resistant tumours by dual T cell plus NK cell attack.
Soumya Badrinath, Maxence O Dellacherie, +14 authors, Kai W Wucherpfennig.
Nature, 2022 May 26;. PMID: 35614223